Skip to main content
SpringerLink
Log in

Pharmacology of Sleep

  • Chapter
  • First Online:
Essentials of Sleep Medicine

Part of the book series: Respiratory Medicine ((RM))

  • 2563 Accesses

Abstract

Drugs that modulate sleep and wakefulness operate by modifying the activity of key sleep–wake neurotransmitters in the brain. Wakefulness-promoting nuclei include the orexinergic lateral hypothalamus, the histaminergic tuberomammillary nucleus, the cholinergic pedunculopontine (PPT) and laterodorsal (LDT) tegmental nuclei, the noradrenergic locus coeruleus, the serotonergic raphe nuclei, and the dopaminergic ventral tegmental area (Table 2.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005;437(7063):1257–63.

    PubMed  CAS  Google Scholar 

  2. Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol. 2006;61(6):761–6.

    PubMed  CAS  Google Scholar 

  3. Johnston GA. GABA(A) receptor channel pharmacology. Curr Pharm Des. 2005;11(15):1867–85.

    PubMed  CAS  Google Scholar 

  4. Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother. 1998;32(6):680–91.

    PubMed  CAS  Google Scholar 

  5. Roth T, Roehrs TA. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry. 1991;52 Suppl 9:S38–41.

    Google Scholar 

  6. Mendelson WB. Clinical distinctions between long-acting and short-acting benzodiazepines. J Clin Psychiatry. 1992;53 Suppl 12:S4–7.

    Google Scholar 

  7. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225–33.

    PubMed  CAS  Google Scholar 

  8. Nowell PD, Mayumdar S, Buysse DJ, Dew MA, Reynolds CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997;278:2170–7.

    PubMed  CAS  Google Scholar 

  9. Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology. 1995;51:205–23.

    PubMed  CAS  Google Scholar 

  10. Fava M, Asnis GM, Shrivastava R, Lydiard B, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(3):222–30.

    PubMed  CAS  Google Scholar 

  11. Staner L, Eriksson M, Cornette F, et al. Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study. Sleep Med. 2009;10:616–20.

    PubMed  CAS  Google Scholar 

  12. Hajak G, Müller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98(10):1371–8.

    PubMed  CAS  Google Scholar 

  13. Elie R, Rüther E, Farr I, Emilien G, Salinas E. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry. 1999;60(8):536–44.

    PubMed  CAS  Google Scholar 

  14. Danjou P, Paty I, Fruncillo R, Worthington P, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol. 1999;48(3):367–74.

    PubMed  CAS  Google Scholar 

  15. Chiang A, Krystal A. Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent. J Clin Sleep Med. 2008;4(2):155–6.

    PubMed  Google Scholar 

  16. Zammit G, Wang-Weigand S, Rosenthal M, Peng X. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med. 2009;5(1):34–40.

    Google Scholar 

  17. Holm K, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59:865–89.

    PubMed  CAS  Google Scholar 

  18. Fry J, Scharf M, Mangano R, Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int Clin Psychopharmacol. 2000;15(3):141–52.

    PubMed  CAS  Google Scholar 

  19. Allain H, Bentué-Ferrer D, Breton SL, et al. Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg. Hum Psychopharmacol. 2003;18(5):369–74.

    PubMed  CAS  Google Scholar 

  20. Perlis ML, McCall WV, Krystal AD, et al. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry. 2004;65:1128–37.

    PubMed  CAS  Google Scholar 

  21. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T, ZOLONG Study Group. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31(1):79–90.

    PubMed  Google Scholar 

  22. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793–9.

    PubMed  Google Scholar 

  23. Cluydts R, Peeters K, DeBouyalisky I, et al. Comparison of continuous vs. intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized, pilot study. J Int Med Res. 1998;26:13–24.

    PubMed  CAS  Google Scholar 

  24. Hajak G, Cluydts R, Declerck A, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol. 2002;17:9–17.

    PubMed  CAS  Google Scholar 

  25. Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep. 2000;23:1087–96.

    PubMed  CAS  Google Scholar 

  26. Erman M, Guiraud A, Joish VN, Lerner D. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep. 2008;31(10):1371–8.

    PubMed  Google Scholar 

  27. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979–91.

    PubMed  CAS  Google Scholar 

  28. Roth T, Walsh JK, Krystal A, Wessel T, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6:487–95.

    PubMed  Google Scholar 

  29. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28:720–7.

    PubMed  Google Scholar 

  30. McCall WV, Erman M, Krystal AD, et al. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin. 2006;22:1633–42.

    PubMed  CAS  Google Scholar 

  31. Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med. 2008;4(3):229–34.

    PubMed  Google Scholar 

  32. Krystal AD, Erman M, Zammit GK, Soubrane C, Roth T. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep. 2008;31:79–90.

    PubMed  Google Scholar 

  33. Krystal A. A compendium of placebo-controlled trials of the risks/benefits of pharmacologic treatments for insomnia: the empirical basis for clinical practice. Sleep Med Rev. 2009;13:265–74.

    PubMed  Google Scholar 

  34. Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep. 2010;33(2):225–34.

    PubMed  Google Scholar 

  35. Joffe H, Petrillo L, Viguera A, Koukopoulos A, Silver-Heilman K, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol. 2010;202(2):171.

    PubMed  Google Scholar 

  36. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007;30:959–68.

    PubMed  Google Scholar 

  37. Snedecor SJ, Botteman MF, Bojke C, et al. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep. 2009;32(6):817–24.

    PubMed  Google Scholar 

  38. Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004;19:305–22.

    PubMed  Google Scholar 

  39. Roth T, Roehrs TA. Issues in the use of benzodiazepine therapy. J Clin Psychiatry. 1992;53 Suppl 6:S14–8.

    Google Scholar 

  40. Mello de Paula AJ. Comparative study of zopiclone and pentobarbitone as hypnotics. Pharmacology. 1983;27 Suppl 2:188–95.

    PubMed  Google Scholar 

  41. Dubocovich ML. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med. 2007;8 Suppl 3:34–42.

    PubMed  Google Scholar 

  42. Liu C, Weaver DR, Jin X, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102.

    PubMed  CAS  Google Scholar 

  43. Dubocovich ML, Yun K, Al-Ghoul WM, et al. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998;12:1211–20.

    PubMed  CAS  Google Scholar 

  44. Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301–10.

    PubMed  CAS  Google Scholar 

  45. Markwald RR, Lee-Choing TL, Burke TM, et al. Effects of the melatonin MT-1/MT-2 agonist ramelteon on daytime body temperature and sleep. Sleep. 2010;33(6):825–31.

    PubMed  Google Scholar 

  46. Available from: http://www.rozerem.com.Accessed August 2011.

  47. Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006;46(2):140–8.

    PubMed  CAS  Google Scholar 

  48. Greenblatt DJ, Harmatz JS, Karim A. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007;47(4):485–96.

    PubMed  CAS  Google Scholar 

  49. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006;7:17–24.

    PubMed  Google Scholar 

  50. Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006;63:1149–57.

    PubMed  CAS  Google Scholar 

  51. Obach RS, Ryder TF. Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010;38(8):1381–91.

    PubMed  CAS  Google Scholar 

  52. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23:1005–14.

    PubMed  CAS  Google Scholar 

  53. Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006;7(4):312–8.

    PubMed  Google Scholar 

  54. Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009;32(3):351–60.

    PubMed  Google Scholar 

  55. Richardson G, Wang-Weigand S. Effects of long-term exposure to ramelteon, a melatonin receptor agonist, on endocrine function in adults with chronic insomnia. Hum Psychopharmacol. 2009;24(2):103–11.

    PubMed  CAS  Google Scholar 

  56. Roth T, Stubbs C, Walsh JK. Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005;28(3):303–7.

    PubMed  Google Scholar 

  57. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979–91.

    PubMed  CAS  Google Scholar 

  58. Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3(5):495–504.

    PubMed  Google Scholar 

  59. Zammit G, Schwartz H, Roth T, Wang-Weigand S, Sainati S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med. 2009;10(1):55–9.

    PubMed  Google Scholar 

  60. Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath. 2008;12(3):243–50.

    PubMed  Google Scholar 

  61. Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. 2009;13(1):79–84.

    Google Scholar 

  62. Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry. 2009;70(4):467–76.

    Google Scholar 

  63. Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother. 2007;5(3):177–84.

    Google Scholar 

  64. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a metaanalysis. Sleep Med Rev. 2005;9:41–50.

    PubMed  Google Scholar 

  65. Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. Sleep Med Rev. 2002;6:407–20.

    PubMed  Google Scholar 

  66. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005;9:25–39.

    PubMed  Google Scholar 

  67. Srinivasan V, Singh J, Pandi-Perumal SR, et al. Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs. Adv Ther. 2010;27(11):796–813.

    PubMed  CAS  Google Scholar 

  68. Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep. 2007;30(11):1445–59.

    PubMed  Google Scholar 

  69. Sack RL, Brandes RW, Kendall AR, et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000;343:1070–7.

    PubMed  CAS  Google Scholar 

  70. Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.

    PubMed  Google Scholar 

  71. Luboshizsky R, Lavie P. Sleep-inducing effects of exogenous melatonin administration. Sleep Med Rev. 1998;2(3):191–202.

    PubMed  CAS  Google Scholar 

  72. Nierenberg AA, Adler LA, Peselow E, et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151(7):1069–72.

    PubMed  CAS  Google Scholar 

  73. Scharf MB, Sachais BA. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry. 1990;51 Suppl 9:S13–7.

    Google Scholar 

  74. Kaynak H, Kaynak D, Gözükirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Med. 2004;5:15–20.

    PubMed  Google Scholar 

  75. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol. 1998;13:191–8.

    CAS  Google Scholar 

  76. Janowsky D, Curtis G, Zisook S, et al. Ventricular arrhythmias possibly aggravated by trazodone. Am J Psychiatry. 1983;140:796–7.

    PubMed  CAS  Google Scholar 

  77. Winkler D, Ortner R, Pjrek E, Aschauer H, Kasper S. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol. 2006;21(1):61–2.

    PubMed  CAS  Google Scholar 

  78. Thompson Jr JW, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry. 1990;51:430–3.

    PubMed  Google Scholar 

  79. James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752–5.

    PubMed  CAS  Google Scholar 

  80. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469–76.

    PubMed  CAS  Google Scholar 

  81. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. 2005;20(8):533–59.

    PubMed  CAS  Google Scholar 

  82. Yamadera H, Nakamura S, Suzuki H, Endo S. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci. 1998;52(4):439–43.

    PubMed  CAS  Google Scholar 

  83. Ware JC. Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry. 1983;44:25–8.

    PubMed  CAS  Google Scholar 

  84. DeMartinis NA, Winokur A. Effects of psychiatric medications on sleep and sleep disorders. CNS Neurol Disord Drug Targets. 2007;6(1):17–29.

    PubMed  CAS  Google Scholar 

  85. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927–47.

    PubMed  CAS  Google Scholar 

  86. Hajak G, Rodenbeck A, Voderhozer U, et al. Doxepin in the treatment of primary insomnia; a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry. 2001;62:453–63.

    PubMed  CAS  Google Scholar 

  87. Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007;30(11):1555–61.

    PubMed  Google Scholar 

  88. Scharf M, Rogowski R, Hull S, Cohn M, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2008;69(10):1557–64.

    PubMed  CAS  Google Scholar 

  89. Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33(11):1553–61.

    PubMed  Google Scholar 

  90. Beasley Jr CM, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol. 1992;12:328–33.

    PubMed  Google Scholar 

  91. Armitage R, Trivedi M, Rush AJ. Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology. 1995;12(2):159–65.

    PubMed  CAS  Google Scholar 

  92. Geyer JD, Carney PR, Dillard SC, et al. Antidepressant medications, neuroleptics, and prominent eye movements during NREM sleep. J Clin Neurophysiol. 2009;26(1):39–44.

    PubMed  Google Scholar 

  93. Winkelman JW, James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep. 2004;27(2):317–21.

    PubMed  Google Scholar 

  94. Oberndorfer S, Saletu-Zyhlarz G, Saletu B. Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology. 2000;42(2):69–81.

    PubMed  CAS  Google Scholar 

  95. Lu BS, Zee PC. Neurobiology of sleep. Clin Chest Med. 2010;31(2):309–18.

    PubMed  Google Scholar 

  96. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs. 2008;22(11):939–62.

    PubMed  CAS  Google Scholar 

  97. Krystal AD, Goforth HW, Roth T. Effects of antipsychotic medications on sleep in schizophrenia. Int Clin Psychopharmacol. 2008;23(3):150–60.

    PubMed  Google Scholar 

  98. Sharpley AL, Attenburrow ME, Hafizi S, Cowen PJ. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. J Clin Psychiatry. 2005;66(4):450–4.

    PubMed  CAS  Google Scholar 

  99. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry. 2000;33:47–53.

    PubMed  CAS  Google Scholar 

  100. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. Neurology. 2002;59:1573–9.

    PubMed  CAS  Google Scholar 

  101. Neubauer DN. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Investig Drugs. 2010;11:101–10.

    PubMed  CAS  Google Scholar 

  102. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954–64.

    PubMed  CAS  Google Scholar 

  103. Quera-Salva MA, Lemoine P, Guilleminault C. Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients. Hum Psychopharmacol. 2010;25(3):222–9.

    PubMed  CAS  Google Scholar 

  104. Leproult R, Van Onderbergen A, L’hermite-Baleriaux M, et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf). 2005;63:298–304.

    CAS  Google Scholar 

  105. Raiteri M, Bertollini A, Angelini F, Levi G. d-Amphetamine as a releaser or reuptake inhibitor of biogenic amines in synaptosomes. Eur J Pharmacol. 1975;34:189–95.

    PubMed  CAS  Google Scholar 

  106. Nicholson AN, Stone BM. Heterocyclic amphetamine derivatives and caffeine on sleep in man. Br J Clin Pharmacol. 1980;9(2):195–203.

    PubMed  CAS  Google Scholar 

  107. Young JW. Dopamine D1 and D2 receptor family contributions to modafinil-induced wakefulness. J Neurosci. 2009;29(9):2663–5.

    PubMed  CAS  Google Scholar 

  108. Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci. 2008;28:8462–9.

    PubMed  CAS  Google Scholar 

  109. Ishizuka T, Murotani T, Yamatodani A. Modanifil activates the histaminergic system through the orexinergic neurons. Neurosci Lett. 2010;483(3):193–6.

    PubMed  CAS  Google Scholar 

  110. Willie JT, Renthal W, Chemelli RM, et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience. 2005;30:983–95.

    Google Scholar 

  111. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20:8620–8.

    PubMed  CAS  Google Scholar 

  112. Beck P, Odle A, Wallace-Huitt T, Skinner RD, Garcia-Rill E. Modafinil increases arousal determined by P13 potential amplitude: an effect blocked by gap junction antagonists. Sleep. 2008;31(12):1647–54.

    PubMed  Google Scholar 

  113. Available from: http://www.provigil.com/media/PDFs/prescribing_info.pdf. Accessed August 2011.

  114. Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–11.

    PubMed  Google Scholar 

  115. Schwartz JRL. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.

    PubMed  Google Scholar 

  116. Golicki D, Bala MM, Niewada M, Wierzbicka A. Modafinil for narcolepsy: systematic review and meta-analysis. Med Sci Monit. 2010;16(8):RA177–86.

    PubMed  Google Scholar 

  117. Besset A, Tafti M, Villemin E, Billiard M. The effects of modafinil (300 mg) on sleep, sleepiness and arousal in narcoleptic patients. Neurophysiol Clin. 1993;23(1):47–60.

    PubMed  CAS  Google Scholar 

  118. Billiard M, Besset A, Montplaisir J, et al. Modafi nil: a double-blind multicentric study. Sleep. 1994;17:S107–12.

    PubMed  CAS  Google Scholar 

  119. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–46.

    PubMed  Google Scholar 

  120. Boivin DB, Montplaisir J, Petit D, Lambert C, Lubin S. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol. 1993;16(1):46–53.

    PubMed  CAS  Google Scholar 

  121. Broughton RJ, Fleming JAE, George CFP, et al. Randomised, doubleblind, placebo-controlled crossover trial of modafi nil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49:444–51.

    PubMed  CAS  Google Scholar 

  122. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 2000;1:109–16.

    PubMed  Google Scholar 

  123. Saletu MT, Anderer P, Saletu-Zyhlarz GM, Mandl M, Arnold O, Nosiska D, et al. EEG-mapping differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil. Eur Arch Psychiatry Clin Neurosci. 2005;255(1):20–32.

    PubMed  Google Scholar 

  124. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 1998;43:88–97.

    Google Scholar 

  125. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology. 2000;54:1166–75.

    Google Scholar 

  126. Beuersterien KM, Rogers AAE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999;22:757–65.

    Google Scholar 

  127. Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol. 2003;26(5):252–7.

    PubMed  CAS  Google Scholar 

  128. Rossetti AO, Heinzer RC, Tafti M, Buclin T. Rapid occurrence of depression following addition of sodium oxybate. Sleep Med. 2010;11:500–1.

    PubMed  Google Scholar 

  129. Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med. 2001;164(9):1675–81.

    PubMed  CAS  Google Scholar 

  130. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005;2005(28):464–71.

    Google Scholar 

  131. Hirshkowitz M, Black J. Effect of adjunctive modafinil on wakefulness and quality of life in patients with excessive sleepiness-associated obstructive sleep apnoea/hypopnoea syndrome: a 12-month, open-label extension study. CNS Drugs. 2007;21(5):407–16.

    PubMed  CAS  Google Scholar 

  132. Weaver TE, Chasens ER, Arora S. Modafinil improves functional outcomes in patients with residual excessive sleepiness associated with CPAP treatment. J Clin Sleep Med. 2009;5(6):499–505.

    PubMed  Google Scholar 

  133. Czeisler CA, Walsh JK, Roth T, Hughes RJ, Wright KP, Kingsbury L, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med. 2005;353(5):476–86.

    PubMed  CAS  Google Scholar 

  134. Roth T, Schwartz JR, Hirshkowitz M, Erman MK, et al. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med. 2007;3(6):595–602.

    PubMed  Google Scholar 

  135. Kaiser PR, Valko PO, Werth E, Thomann J, et al. Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology. 2010;75(20):1780–5.

    PubMed  CAS  Google Scholar 

  136. Ali M, Auger RR, Slocumb NL, Morgenthaler TI. Idiopathic hypersomnia: clinical features and response to treatment. J Clin Sleep Med. 2009;5(6):562–8.

    PubMed  Google Scholar 

  137. Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother. 2010;44(6):1098–103.

    PubMed  CAS  Google Scholar 

  138. Peuckmann V, Elsner F, Krumm N, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev. 2010;11:CD006788.

    PubMed  Google Scholar 

  139. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med. 2007;101(3):616–27.

    PubMed  CAS  Google Scholar 

  140. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006;28(5):689–706.

    PubMed  CAS  Google Scholar 

  141. Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761–74.

    PubMed  CAS  Google Scholar 

  142. Czeisler CA, Walsh JK, Wesnes KA, Arora S, Roth T. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clin Proc. 2009;84(11):958–72.

    PubMed  CAS  Google Scholar 

  143. Black JE, Hull SG, Tiller J, Yang R, Harsh JR. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. J Clin Sleep Med. 2010;6(5):458–66.

    PubMed  Google Scholar 

  144. Schwartz JR, Khan A, McCall WV, Weintraub J, Tiller J. Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month, open-label, flexible-dose study with an extension period. J Clin Sleep Med. 2010;6(5):450–7.

    PubMed  Google Scholar 

  145. Rosenberg RP, Bogan RK, Tiller JM, Yang R, et al. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin Proc. 2010;85(7):630–8.

    PubMed  CAS  Google Scholar 

  146. Schwartz TL, Siddiqui UA, Raza S, Morell M. Armodafinil for fibromyalgia fatigue. Ann Pharmacother. 2010;44(7–8):1347–8.

    PubMed  Google Scholar 

  147. Borgen LA, Okerholm R, Morrison D, et al. The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol. 2003;43:59–65.

    PubMed  CAS  Google Scholar 

  148. Ferrara SD, Tedeschi L, Frison G, et al. Effect of moderate or severe liver dysfunction on the pharmacokinetics of [gamma]-hydroxybutyric acid. Eur J Clin Pharmacol. 1996;50:305–10.

    PubMed  CAS  Google Scholar 

  149. Scharf MB, Lai AA, Branigan B, et al. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep. 1998;21:507–14.

    PubMed  CAS  Google Scholar 

  150. Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004;27(7):1327–34.

    PubMed  Google Scholar 

  151. US Xyrem[R] Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42–9.

    Google Scholar 

  152. US Xyrem[R] Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26(1):31–5.

    Google Scholar 

  153. Xyrem[R] International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391–7.

    Google Scholar 

  154. Xyrem[R] International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005;6(5):415–21.

    Google Scholar 

  155. Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009;10(8):829–35.

    PubMed  Google Scholar 

  156. Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep. 2006;29(9):1189–94.

    PubMed  Google Scholar 

  157. US XYREM® Multicenter Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol. 2003;41:131–5.

    Google Scholar 

  158. Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy. 2001;21(12):1486–513.

    PubMed  CAS  Google Scholar 

  159. Rundell OH, Lester BK, Griffiths WJ, Williams HL. Alcohol and sleep in young adults. Psychopharmacologia (Berl). 1972;26:201–18.

    CAS  Google Scholar 

  160. Schierenbeck T, Riemann D, Berger M, Hornyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev. 2008;12(5):381–9.

    PubMed  Google Scholar 

  161. Johanson CE, Roehrs T, Schuh K, et al. The effects of cocaine on mood and sleep in cocaine-dependent males. Exp Clin Psychopharmacol. 1999;7(4):338–46.

    PubMed  CAS  Google Scholar 

  162. Green AR, Mechan AO, Elliott JM, et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev. 2003;55(3):463–508.

    PubMed  CAS  Google Scholar 

  163. McCann UD, Peterson SC, Ricaurte GA. The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users. Neuropsychopharmacology. 2007;32:1695–706.

    PubMed  CAS  Google Scholar 

  164. McCann UD, Ricaurte GA. Effects of (+/−) 3,4-methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. Scientific World J. 2007;7:231–8.

    Google Scholar 

  165. Kales A, Hanley J, Rickles W, et al. Effects of marijuana administration and withdrawal in chronic users and naiıve 7subjects. Psychophysiology. 1972;9:92.

    Google Scholar 

  166. Feinberg I, Jones R, Walker JM, et al. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther. 1975;17(4):458–66.

    PubMed  CAS  Google Scholar 

  167. Nicholson AN, Turner C, Stone BM, et al. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J Clin Psychopharmacol. 2004;24(3):305–13.

    PubMed  CAS  Google Scholar 

  168. Karacan I, Fernandez-Salas A, Coggins WJ, et al. Sleep electroencephalographiceelectrooculographic characteristics of chronic marijuana users: part I. Ann N Y Acad Sci. 1976;282:348–74.

    PubMed  CAS  Google Scholar 

  169. Kay DC. Human sleep during chronic morphine intoxication. Psychopharmacologia. 1975;44(2):117–24.

    PubMed  CAS  Google Scholar 

  170. Walker JM, Farney RJ, Rhondeau SM, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med. 2007;3(5):455–61.

    PubMed  Google Scholar 

  171. Wang D, Teichtahl H. Opioids, sleep architecture and sleep-disordered breathing. Sleep Med Rev. 2007;11(1):35–46.

    PubMed  Google Scholar 

  172. Iannone R, Palcza J, Renger JJ, et al. Acute alertness-promoting effects of a novel histamine subtype-3 receptor inverse agonist in healthy sleep-deprived male volunteers. Clin Pharmacol Ther. 2010;88(6):831–9.

    PubMed  CAS  Google Scholar 

  173. Gemkow MJ, Davenport AJ, Harich S, et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today. 2009;14:509–15.

    PubMed  CAS  Google Scholar 

  174. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H-3 receptor improves wakefulness in narcolepsy: studies in orexin(−/−) mice and patients. Neurobiol Dis. 2008;30(1):74–83.

    PubMed  Google Scholar 

  175. Mignot E, Nishino S. Emerging therapies in narcolepsy-cataplexy. Sleep. 2005;28(6):754–63.

    PubMed  Google Scholar 

  176. Nishino S, Arrigoni J, Shelton J, et al. Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci. 1997;17:6401–8.

    PubMed  CAS  Google Scholar 

  177. Hirai K, Kita M, Ohta H, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms. 2005;20(1):27–37.

    Google Scholar 

  178. Available from: http://www.lunesta.com/PostedApprovedLabelingText.pdf. Accessed August 2011.

  179. Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry. 2000;48(1):75–8.

    PubMed  CAS  Google Scholar 

  180. Shen J, Chung SA, Kayumov L, Moller H, et al. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry. 2006;51(1):27–34.

    PubMed  Google Scholar 

  181. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63 Suppl 13:5–11.

    PubMed  CAS  Google Scholar 

  182. Cohrs S, Rodenbeck A, Guan Z, et al. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl). 2004;174:421–9.

    CAS  Google Scholar 

  183. US Food and Drug Administration (FDA). Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_05_06_MixedSaltFDAlabel.pdf. Accessed August 2011.

  184. Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry. 2005;58(6):510–4.

    PubMed  CAS  Google Scholar 

  185. Xyrem[R] (sodium oxybate) oral solution. Jazz Pharmaceuticals Inc [online]. Available from: http://www.jazzpharma.com/content/xpi_2011.pdf. Accessed August 2011.

  186. Roux FJ, Kryger MH. Medication effects on sleep. Clin Chest Med. 2010;31(2):397–405.

    PubMed  Google Scholar 

  187. Zee PC, Wang-Weigand S, Wright KP Jr, et al. Effects of ramelteon on insomnia symptoms induced by rapid, eastward travel. Sleep Med. 2010;11(6):525–33.

    Google Scholar 

  188. Richardson GS, Zee PC, Wang-Weigand S, Rodriguez L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med. 2008;4(5):456–61.

    Google Scholar 

  189. Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009;373 (9662):482–91.

    Google Scholar 

  190. (Available from: http://products.sanofi-aventis.us/ambien/ambien.html. Accessed Nov 2010). Accessed August 2011.

    PubMed  CAS  Google Scholar 

  191. http://www.pfizer.com/files/products/uspi_sonata_civ.pdf. Accessed August 2011.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgement

Career Development Award from the Department of Veterans Affairs.

Author information

Authors and Affiliations

  1. Sleep Medicine Section, Medical Service, John D. Dingell VA Medical Center and Wayne State University, Detroit, MI, USA

    Susmita Chowdhuri

Authors
  1. Susmita Chowdhuri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susmita Chowdhuri .

Editor information

Editors and Affiliations

  1. Harper University Hospital, Div. Pulmonary, Allergy, Critical, Wayne State University, John R. Street 3990, Detroit, 48201, Michigan, USA

    M. Safwan Badr

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Chowdhuri, S. (2012). Pharmacology of Sleep. In: Badr, M. (eds) Essentials of Sleep Medicine. Respiratory Medicine. Humana Press. https://doi.org/10.1007/978-1-60761-735-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-735-8_2

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-734-1

  • Online ISBN: 978-1-60761-735-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation